Page 82 - XXIV Monografías en Esclerosis Múltiple

FUNDAMENTOS INMUNOLÓGICOS DEL TRATAMIENTO DE LA ESCLEROSIS MÚLTIPLE
82
19. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface mol- ecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol. 1993;121:1121-32.
20. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol. 2012;142:31-7.
21. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, et al. Rituximab ef- ficiently depletes increased CD20-expressing T cells in multiple sclerosis patients. J Immunol. 2014;193:580-6.
22. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al.; OPERA I and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376:221-34.
23. Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, et al.; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909-20.
24. Fiore K. Genetech reports PML case with ocrelizumab. MedPage Today; 2017. Disponible en: https://www.medpagetoday.com/neurology/multiplesclerosis/65537.
25. Ficha técnica Mavenclad (consultado el 14 de mayo de 2018). http://www.ema.europa.eu/docs/ en_GB/document_library/EPAR_-_Product_Information/human/004230/WC500234561.pdf
26. Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Cladribine as a therapeutic option in multiple sclerosis. Clin Immunol. 2012;142:68-75.
27. Pakpoor J, Disanto G, Altmann DR, Pavitt S, Turner BP, Marta M, et al. No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroin- flamm. 2015 Oct 1;2(6):e158.
28. Schreiber K, Sorenser P. Cladribine in the treatment of multiple sclerosis. Clin Invest. 2011;1:317-26.